Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity

详细信息    查看全文

• 作者：Cristiane Oliveira ; Gustavo Jacob Lourenço ; José Augusto Rinck-Junior…
• 关键词：Cutaneous melanoma ; Apoptosis ; Genetic polymorphism ; Prognosis
• 刊名：Medical Oncology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：34
• 期：2
• 全文大小：
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X
• 卷排序：34

文摘

Cutaneous melanoma (CM) cells are resistant to apoptosis, and steroid hormones are involved in this process through regulation of TP53, MDM2, BAX, and BCL2 expression. We analyzed herein sex differences in outcomes of CM patients associated with TP53 c.215G>C, MDM2 c.309T>G, BAX c.−248G>A, and BCL2 c.−717C>A polymorphisms. DNA from 121 men and 116 women patients was analyzed by polymerase chain reaction and enzymatic digestion assays. At 60 months of follow-up, shorter progression-free survival (PFS) was seen in males with MDM2 GG + BCL2 AA (20.0 vs. 62.6%, P = 0.0008) genotype. Men carriers of the genotype had poor PFS (HR 3.78, 95% CI 1.30–11.0) than others. For women, shorter PFS was associated with TP53 GC or CC (61.4 vs. 80.8%, P = 0.01) and TP53 GC or CC + MDM2 TG or GG (59.1 vs. 85.4%, P = 0.01) genotypes at the same time. Women carriers of the genotypes had poor PFS (HR 2.46, 95% CI 1.19–5.09; HR 9.49, 95% CI 1.14–78.50) than others, respectively. Our data present, for the first time, preliminary evidence that inherited abnormalities on TP53, MDM2 and BCL2 genes, enrolled in apoptosis pathways, have a pivotal role in differences of outcomes in women and men with CM.